Sloning Further Strengthens its Intellectual Property with New US Patent

Puchheim, Germany – April 13, 2010 / b3c newswire / – Sloning, leading supplier of synthetic biology tools was awarded US Patent No, 7,695,906. Sloning’s enabling platform technology - Slonomics® - allows researchers to increase the success rate of their screening for new and optimized therapeutic antibodies, proteins or industrial enzymes.

Key to Sloning’s success is the company’s core technology, Slonomics®, a patented technology that uses a set of double stranded DNA triplets as universal building blocks for the synthesis of combinatorial libraries - 'one codon at a time'. For library production, multiple codons can be introduced in parallel at any desired sequence position. The absence of functional bias and the ability to select and precisely control delivery of up to 20 codons at any ratio results in exceptionally high quality libraries containing the complete set of desired mutants. In addition, mutated regions of varying length can also be incorporated in the design.

With over 1000 combinatorial libraries fabricated since the introduction of the Slonomics® technology at the end of April 2008, Sloning has established a market leadership position and serves the majority of the world’s top 50 protein engineering and pharmaceutical companies. Sloning´s technology affords their customers the ability to precisely design an antibody and enzyme library to their exact specifications.

“The granted patent represents another key step in the ongoing development of our technology portfolio and allows the company to focus its efforts on developing additional innovative products and services for the protein and antibody engineer” says Dr. Jan Van den Brulle, Scientific Director of Sloning R&D.

About Sloning BioTechnology GmbH - www.sloning.com

Sloning BioTechnology GmbH established in December 2000,
based in Puchheim, close-by Munich, Germany

Technology:	Slonomics®
Business:	combinatorial libraries (SlonoMax®) protein and expression optimization
Funding:	venture capital (HBM Partners, DEWB, LBBW-VC, KfW)

For more information about Sloning, please visit www.sloning.com

Contacts

Dr. Heinz Schwer, Chief Executive Officer, h.schwer@sloning.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Dr. Gudrun Horn, Product Manager, g.horn@sloning.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Sloning BioTechnology GmbH

Zeppelinstr. 4
82178 Puchheim
Germany
T: +49 89 8090950
E: info@sloning.com
W: www.sloning.com